Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1”

1,536 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,536 results

Large-scale testing (Phase 3)Study completedNCT01866319
What this trial is testing

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 834
Testing effectiveness (Phase 2)Study completedNCT03463681
What this trial is testing

CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma

Who this might be right for
Metastatic Renal Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 49
Testing effectiveness (Phase 2)Looking for participantsNCT06001658
What this trial is testing

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Who this might be right for
Billiary Track Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27
Not applicableLooking for participantsNCT06804135
What this trial is testing

Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer

Who this might be right for
Cervical Carcinoma
Tata Memorial Hospital 110
Early research (Phase 1)Study completedNCT02827968
What this trial is testing

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumors
3D Medicines (Sichuan) Co., Ltd. 28
Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Not applicableLooking for participantsNCT04629326
What this trial is testing

PD-L1 Targeting Molecular Imaging of Solid Tumors

Who this might be right for
Gastrointestinal Tumors
Peking University Cancer Hospital & Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT07169552
What this trial is testing

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

Who this might be right for
NSCLC
HC Biopharma Inc. 50
Not applicableNot Yet RecruitingNCT06682247
What this trial is testing

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Feng Wang 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Large-scale testing (Phase 3)UnknownNCT05042375
What this trial is testing

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 450
Testing effectiveness (Phase 2)Looking for participantsNCT06070012
What this trial is testing

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Who this might be right for
Uveal Melanoma
Diwakar Davar 44
Large-scale testing (Phase 3)UnknownNCT04203485
What this trial is testing

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
PD-L1 Positive Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 762
Large-scale testing (Phase 3)Study completedNCT04776148
What this trial is testing

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Who this might be right for
Colorectal Neoplasms
Merck Sharp & Dohme LLC 563
Testing effectiveness (Phase 2)WithdrawnNCT04754815
What this trial is testing

Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerAdvanced Lung Non-Small Cell CarcinomaPD-L1 Gene Mutation
Shirish Gadgeel
Testing effectiveness (Phase 2)Looking for participantsNCT06769113
What this trial is testing

A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy

Who this might be right for
Esophageal Cancer
Shanghai Henlius Biotech 72
Large-scale testing (Phase 3)Ended earlyNCT04128696
What this trial is testing

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Neoplasms, Head and Neck
GlaxoSmithKline 315
Large-scale testing (Phase 3)Looking for participantsNCT06357533
What this trial is testing

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 675
Early research (Phase 1)Study completedNCT02738489
What this trial is testing

Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

Who this might be right for
Advanced Melanoma
Jiangsu HengRui Medicine Co., Ltd. 36
Testing effectiveness (Phase 2)Study completedNCT03797326
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerOvarian Cancer+5 more
Merck Sharp & Dohme LLC 611
Load More Results